Labcorp takes step to protect at-risk patients from severe chemotherapy side effects
Labcorp has introduced an expanded DPYD genotyping test that detects key variants to identify patients at risk of severe side effects from fluoropyrimidine chemotherapy, supporting personalized treatment plans.
Labcorp has unveiled an expanded version of its DPYD Genotyping test for personalized cancer care. The test detects patients who are at risk of experiencing severe side effects after receiving fluoropyrimidine chemotherapy, according to an announcement.
With this release, “Labcorp now offers genotype testing for all DPYD Tier 1 and Tier 2 variants recommended by the Association for Molecular Pathology (AMP).” By detecting DPYD variants before patients undergo chemo, Labcorp’s test can help lead to the prevention of about “1,300 deaths in the United States” annually.
Organizations such as the U.S. Food and Drug Administration (FDA) and the National Comprehensive Cancer Network (NCCN) recommend testing for DPYD variants before 5-FU or capecitabine treatment in most cases, according to Labcorp.
